TB-500: Identity and Evidence Boundaries

Scope of this reference

This page concerns the catalogue identity of TB-500 as a laboratory material and the boundaries of what published evidence and batch analysis establish. It is not a treatment guide, a recommendation, a human-use protocol or evidence that the material is safe or effective in people or animals.

TB-500 and thymosin beta-4 are not the same molecule

Thymosin beta-4 (often written Tβ4) is a naturally occurring protein of 43 amino acid residues. TB-500 is a shorter synthetic peptide corresponding to a partial region of that protein.

The two names are routinely used interchangeably in material descriptions. They should not be. A fragment and its parent protein differ in length, mass and structure, and evidence generated with one does not transfer to the other without data specific to the fragment.

This matters more for this material than for most, because the great majority of indexed literature sits under the protein name while the material supplied is the fragment. The listed material is TB-500, which appears in the tissue signalling collection.

Why the actin-binding region is the identity fact

The region of thymosin beta-4 that TB-500 corresponds to is the part described in the literature as interacting with actin, a structural protein of the cytoskeleton. That is a statement about molecular interaction observed in experimental systems, not a statement about an effect in an organism.

Descriptions that move from "binds actin in vitro" to an implied physiological result have crossed from identity into outcome, and the published record does not support that step.

Reading the evidence by tier

• •In-vitro — assays, cell lines and isolated tissue. Establishes behaviour in that system only.
• •Animal models — predominantly rodent. Establishes findings in that species under those conditions.
• •Human data — the tier where claims about people could be grounded, and the tier where the record for this fragment is effectively absent.

A further caution specific to TB-500: a portion of the animal literature uses the full-length protein rather than the fragment. When reading any claim, check which molecule was actually administered in the cited work.

A note on blends

TB-500 is also supplied in a combined presentation with BPC-157, listed among the research blends. Combining two materials in one vial does not generate evidence about the combination, and no published literature addresses this pairing as a pairing. The identity and evidence comparison sets out what separates the two materials.

What analytical documentation establishes

A certificate of analysis provides evidence about the particular batch tested — its identity, measured composition and purity by the stated method. It does not establish a biological, therapeutic or physiological outcome, and it does not extend to other batches.

Because fragment and full-length protein are distinguishable analytically, the batch report is also the document that confirms which molecule was supplied. Available reports are published in our COA library; the guides to reading a peptide COA and understanding HPLC purity explain what those documents can and cannot show.

Laboratory-use boundary

Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.

We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.